Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer

Shanghai Pulmonary Hospital, Shanghai, China

Status and phase: Not yet enrolling; Phase 2

Conditions: Lung Cancer Non-small Cell Stage IV

Treatments: Drug: Almonertinib

Study type: Interventional

Funder types: Other

Identifiers

NCT06463171

2024LY0323

Details and patient eligibility

About

The goal of this clinical trial is to test in Locally Advanced or Metastatic Non-small Cell Lung Cancer patients with EGFR Mutations. The main question it aims to answer is:

Evaluation of the Efficacy and Safety of Aumolertinib in Combination with Lastet for the Treatment of EGFR-Mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer in First-line Therapy.

Participants will be treated with a combination of Aumolertinib and Lastet.

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Prior to the implementation of any trial-related procedures, written informed consent must be obtained.
• Age ≥18 years.
• Patients with locally advanced (Stage III B/III C), metastatic, or recurrent (Stage IV) non-small cell lung cancer (NSCLC) confirmed histologically or cytologically, who are ineligible for surgical intervention and cannot undergo curative radiochemotherapy, as per the 8th edition TNM staging classification of the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer.
• Provide archived tumor tissue or tissue obtained from biopsy at screening for biomarker testing, including EGFR mutation status, etc.;
• Presence of EGFR positive mutation;
• Investigator confirmation of at least one measurable lesion according to RECIST 1.1 criteria.
• Patients who have previously received platinum-containing adjuvant chemotherapy/radiotherapy, neoadjuvant chemotherapy/radiotherapy, or radical radiochemotherapy for advanced disease, with disease progression occurring >6 months after the last treatment, may participate in this study;
• Expected life expectancy ≥3 months.
• ECOG PS 0-1.
• Adequate hematologic function, defined as an absolute neutrophil count ≥1.5×10^9/L, platelet count ≥100×10^9/L, hemoglobin ≥90g/L (without a history of blood transfusion in the past 7 days).
• Adequate liver function, defined as total bilirubin level ≤1.5 times the upper limit of normal (ULN) and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤2.5 times ULN for all patients, or for patients with liver metastasis, AST and ALT levels ≤5 times ULN.
• Adequate renal function, defined as serum creatinine ≤1.5 times ULN.
• Adequate coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) ≤1.5 times ULN; if a subject is on anticoagulant therapy, INR/PT should be within the therapeutic range set by the anticoagulant.
• Women of childbearing potential must undergo a pregnancy test within 7 days prior to the start of treatment, with negative results; and reliable contraception methods (such as intrauterine devices, oral contraceptives, and condoms) should be used during the trial and for 30 days after the end of the trial. Men of childbearing potential should use condoms for contraception during the trial and for 30 days after the end of the trial.
• Willingness to comply with regular follow-up visits and adhere to trial requirements.

Exclusion criteria

• 1. Currently participating in an interventional clinical study treatment;
• Have previously received anti-EGFR treatment;
• Received traditional Chinese medicine with antitumor indications or immunomodulatory drugs (such as thymosin, interferon, interleukin, etc.) within 2 weeks before the first dose;
• Have a history of allergic reactions to any of the study drug components.
• Have active hemoptysis (more than half a teaspoon), active diverticulitis, abdominal abscess, gastrointestinal obstruction, and peritoneal metastasis;
• Have tumor compression of surrounding vital organs (such as the esophagus) with accompanying related symptoms, compression of the superior vena cava, or invasion of major mediastinal vessels, the heart, etc.;
• Known to have brain metastases. Patients judged by the investigator to be asymptomatic or have stable brain metastases may be enrolled;
• Have active systemic infections, including tuberculosis (clinical diagnosis including medical history, physical examination, imaging findings, and TB testing according to local medical routines), hepatitis B (known to be HBV surface antigen (HBsAg) positive, with HBV DNA ≥1000cps/ml or the lower limit of the reference value), hepatitis C, or human immunodeficiency virus (HIV antibody positive);
• Known to have mental illness or substance abuse that may affect compliance with trial requirements;
• Recently treated with a full dose of oral or non-oral anticoagulants or thrombolytics. Prophylactic use of anticoagulants is allowed.
• Have a medical history, disease, treatment, or laboratory abnormality that may interfere with the trial results or prevent the subject from participating in the study throughout, or the investigator considers participation in the study not to be in the best interest of the subject.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

60 participants in 1 patient group

combination therapy

Experimental group

Description:

Almonertinib, dosing regimen: 110mg/day orally, once daily in a 28-day cycle, continuously. Lastet, dosing regimen: 50 mg/day orally, every 28 days in a cycle, two weeks of continuous oral administration, two weeks off.

Treatment:

Drug: Almonertinib